Wendy L. Yarno
Known title: DirectorCIK: 0001181186
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
INO: PGEN AdenoVerse Pipeline May Drive Growth Beyond Papzimeos. The article examines whether PGEN’s AdenoVerse platform can generate growth that surpasses the company’s current Papzimeos product line. It highlights the potential of the pipeline to broaden Inovio’s therapeutic offerings. The discussion comes as the stock sits near its 16‑touch support level of $1.07 and a neutral RSI of 45.6. Analysts still target the shares at around $3.17 on average.
Transaction History
| TARS | ▲ Buy | Option Exercise | 2,954 | — | 6/12/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/13/2025 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,167 | — | 5/21/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| INO | ▲ Buy | Option Exercise | 2,166 | — | 5/15/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 5,000 | — | 12/2/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,000 | — | 6/16/2023 | View on chart |
| INO | ▲ Buy | Option Exercise | 19,000 | — | 5/16/2023 | View on chart |
| INO | ▲ Buy | Option Exercise | 18,000 | — | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.